Senti Biosciences (NASDAQ:SNTI) Stock Price Up 2.2%

Senti Biosciences, Inc. (NASDAQ:SNTI – Get Rating)’s share price traded up 2.2% during trading on Tuesday . The stock traded as high as $1.46 and last traded at $1.41. 28,020 shares traded hands during trading, a decline of 74% from the average session volume of 109,811 shares. The stock had previously closed at $1.38.

Wall Street Analyst Weigh In

SNTI has been the subject of a number of research reports. JPMorgan Chase & Co. initiated coverage on Senti Biosciences in a report on Friday, December 16th. They issued a “neutral” rating for the company. Morgan Stanley reduced their price objective on Senti Biosciences from $7.50 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, January 27th. Finally, Chardan Capital cut their target price on Senti Biosciences from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, January 27th.

Senti Biosciences Price Performance

The company has a fifty day moving average price of $1.65 and a 200-day moving average price of $2.06.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. TD Asset Management Inc. purchased a new stake in shares of Senti Biosciences in the second quarter valued at approximately $172,000. Artal Group S.A. purchased a new stake in Senti Biosciences in the second quarter valued at $2,074,000. Virtu Financial LLC purchased a new stake in Senti Biosciences in the second quarter valued at $43,000. Millennium Management LLC purchased a new stake in Senti Biosciences in the second quarter valued at $71,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Senti Biosciences during the 2nd quarter worth about $6,995,000. Hedge funds and other institutional investors own 40.81% of the company’s stock.

About Senti Biosciences

(Get Rating)

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.